PYC Therapeutics Limited - Splice, Splice Baby: Potential Catalysts Ahead for PYC
We continue to like the risk/reward asymmetry associated with the stock, now without a funding overhang. In the near term, we anticipate multiple...
401 Views
PYC Therapeutics Limited - $146m Capital Raise Removes Funding Overhang
This funds major development across the three current clinical programs, and entry into the clinic for PYC-002 (currently preclinical) in Phelan...
182 Views
ASX Short Interest Weekly (Sep 26th): Washington H Soul Pattinson&Co, Northern Star Resources
We analyzed ASX short interest report for the past week and highlight short interest changes in Washington H Soul Pattinson&Co, Northern Star...
457 Views
PYC Therapeutics Limited - Net Positive VP-001 Update at APVRS
Given our confidence on the safety profile of VP-001 we maintain our price target of $2.40 (VP-001 $0.90, ADPKD $0.90, ADOA $0.40 and PMS $0.20).
194 Views
PYC-003 Shows Positive Preclinical Safety and Efficacy Data in Mice and NHPs
This morning, PYC released preclinical data in two species (mice, non-human primate) for its PYC-003 program in ADPKD (autosomal dominant...
380 Views